We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

15 hedge funds and large institutions have $2.04M invested in AIM ImmunoTech in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more capital invested

Capital invested by funds: $1.4M → $2.04M (+$640K)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GC
Guggenheim Capital
Illinois
+$12.8K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$12.8K
3
VKH
Virtu KCG Holdings
New York
+$12.8K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$12.8K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$6.4K
3
Deutsche Bank
Deutsche Bank
Germany
-$6K
4
TSS
Two Sigma Securities
New York
-$3K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K

AIM Hedge Fund Activity: Q1 2016 in Review

15 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2016, worth a combined $2.04M — up 46% from $1.4M a quarter earlier.

Fund positioning in AIM was balanced in Q1 2016: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Guggenheim Capital, opening a new position worth an estimated $12.8K. The largest seller was Citadel Advisors, cutting an estimated $12.8K.

  • 15 institutional investors held AIM ImmunoTech (AIM) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $2.04M of AIM ImmunoTech stock for Q1 2016, up 46% quarter-over-quarter.
  • 2 funds opened new AIM ImmunoTech positions in Q1 2016 and 2 closed out, a net change of 0 holders.
  • The largest AIM ImmunoTech buyer in Q1 2016 was Guggenheim Capital, an estimated $12.8K added.
  • The largest AIM ImmunoTech seller in Q1 2016 was Citadel Advisors, an estimated $12.8K sold.

Based on aggregated 13F filings for Q1 2016.